Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.71 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.58 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20378369 | 0.85 | MAOB (0.76) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL6041859 | 0.84 | MAOB (0.53) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL12655257 | 0.83 | MAOB (0.73) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL6557580 | 0.83 | MAOB (1.00) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL8359747 | 0.81 | MAOB (0.71) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL292868 | 0.81 | MAOB (0.71) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL2398512 | 0.79 | CYP11B1 (0.77) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL293779 | 0.79 | MAOB (0.67) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL29277424 | 0.79 | MAOB (0.67) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 | |
| SCHEMBL536553 | 0.79 | MAOB (0.67) | MAOBCYP11B1CYP11B2CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636808-B | Chromone-benzoyl hydrazone alpha-glucosidase inhibitor and preparation method and application thereof | 贵州医科大学附属医院 | 2023-10-17 | — | — | CN | claimed |
| CN-115636808-A | Chromone-benzoyl hydrazone alpha-glucosidase inhibitor as well as preparation method and application thereof | 贵州医科大学附属医院 | 2023-01-24 | — | — | CN | claimed |
| EP-4747245-A1 | PHARMACEUTICAL COMPOUNDS | Almac Discovery Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| CN-115636808-B | Chromone-benzoyl hydrazone alpha-glucosidase inhibitor and preparation method and application thereof | 贵州医科大学附属医院 | 2023-10-17 | — | — | CN | disclosed |
| CN-115636808-A | Chromone-benzoyl hydrazone alpha-glucosidase inhibitor as well as preparation method and application thereof | 贵州医科大学附属医院 | 2023-01-24 | — | — | CN | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
| US-5508417-A | FUNGICIDES, BACTERICIDES, ALGICIDE | ROHM AND HAAS COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | MAOB 730/4885CYP11B1 43/4885CYP11B2 50/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | MAOB 730/4885CYP11B1 43/4885CYP11B2 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.